Ataxia is a rare, degenerative neurological disorder that causes loss of muscle control and gradual worsening of motor function. It’s caused by damage to the cerebellum and brainstem, which control the body’s movement and breathing. In this case, the Regentime procedure treats ataxia in patients by replacing damaged tissue with healthy cells using autologous bone marrow derived mononuclear stem cells.

Patients undergoing Regentime treatment report improvements in their daily lives after treatment, including improved balance and coordination, greater ease of performing daily activities (e.g., walking to the bathroom or getting dressed), and more energy.

This procedure is performed on patients via 2 routes; Intravenous and intrathecal (lumbar puncture). This procedure takes 3 to 4 days, with prices ranging from 25,000 USD to 36,700 USD for both routes.